Spots Global Cancer Trial Database for A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Official Title: A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients
Study ID: NCT03437083
Interventions
Study Description
Brief Summary: The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Eisai Trial site_03, Ansan, , Korea, Republic of
Eisai Trial site_04, Busan, , Korea, Republic of
Eisai Trial site_05, Busan, , Korea, Republic of
Eisai Trial site_06, Busan, , Korea, Republic of
Eisai Trial site_09, Daegu, , Korea, Republic of
Eisai Trial site_13, Daejeon, , Korea, Republic of
Eisai Trial site_14, Gwangju, , Korea, Republic of
Eisai Trial site_01, Seoul, , Korea, Republic of
Eisai Trial site_02, Seoul, , Korea, Republic of
Eisai Trial site_07, Seoul, , Korea, Republic of
Eisai Trial site_10, Seoul, , Korea, Republic of
Eisai Trial site_11, Seoul, , Korea, Republic of
Eisai Trial site_12, Seoul, , Korea, Republic of
Eisai Trial site_08, Suwon, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
